AR-1001 by AriBio for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AR-1001 overview
AR-1001 is under development for the treatment of Alzheimer’s disease, vascular dementia, Lewy body dementia, post traumatic stress disorder (PTSD), stroke and amyotrophic lateral sclerosis(ALS). The therapeutic candidate is formulated in tablet form and administered through oral route. The therapeutic candidate acts by targeting phosphodiesterase type 5 (PDE5).
It was under development for the treatment of Parkinson’s disease.
AriBio overview
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
AriBio Co Ltd is a biopharmaceutical business specialising in the development of novel medications to treat diseases including alzheimer’s, sepsis, and obesity. The company is headquartered in Seongnam-si, Gyeonggi-do, Republic of Korea (South Korea).
For a complete picture of AR-1001’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#AR1001 #AriBio #PostTraumatic #Stress #Disorder #PTSD #Likelihood #Approval
